SLNO Q3 2025 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SLNOSoleno Therapeutics, Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$66M

Gross Profit

$65M98.3% margin

Operating Income

$22M33.5% margin

Net Income

$26M39.4% margin

EPS (Diluted)

$0.47

QoQ Revenue Growth

+102.2%

Cash Flow

Operating Cash Flow

$44M

Free Cash Flow

$44M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$600M

Total Liabilities

$105M

Stockholders' Equity

$495M

Cash & Equivalents

$247M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$66M	$0	—
Gross Profit	$65M	$0	—
Operating Income	$22M	-$80M	+127.6%
Net Income	$26M	-$77M	+134.0%